Calidi Biotherapeutics, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Calidi Biotherapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2021 to Q2 2024.
  • Calidi Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$5.77M, a 53.9% increase year-over-year.
  • Calidi Biotherapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$23.2M, a 27.5% increase year-over-year.
  • Calidi Biotherapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$29.2M, a 14.9% decline from 2022.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 -$5.77M +$6.73M +53.9% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$7.23M -$763K -11.8% Mar 31, 2024 10-Q 2024-08-13
Q4 2023 -$8.23M -$473K -6.1% Dec 31, 2023 10-K 2024-03-15
Q3 2023 -$2.02M +$3.33M +62.2% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$12.5M -$7.93M -173% Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$6.46M +$1.28M +16.5% Mar 31, 2023 10-Q 2024-08-13
Q4 2022 -$7.76M Dec 31, 2022 10-K 2024-03-15
Q3 2022 -$5.36M -$4.53M -550% Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$4.58M -$4.49M -5393% Jun 30, 2022 10-Q 2023-11-14
Q1 2022 -$7.74M -$7.74M Mar 31, 2022 10-Q 2023-11-14
Q3 2021 -$823K Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$83.3K Jun 30, 2021 10-Q 2022-11-14
Q1 2021 $0 Mar 31, 2021 10-Q 2022-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.